Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Masimo reports robust Q4 earnings, eyes new product launches

Masimo's Q4 2022 earnings call highlighted strong financial performance, growth projections for 2023, and a focus on innovation and regulatory advancements. While facing challenges like supply chain issues and legal disputes, the company remains optimistic about opportunities in new product launches and revenue growth drivers. Overall, Masimo is poised for continued success in the healthcare market.

Masimo reports robust Q1 earnings, navigates challenges with strategic focus

Masimo's Q1 performance reflects strong revenue growth and product innovation, underpinned by a focus on healthcare technology and wearables for chronic illness monitoring.
While facing challenges such as litigation costs and regulatory clearances, Masimo maintains its financial guidance for 2023, signaling stability and strategic resilience.
The company's emphasis on new product launches, diverse pricing strategies, and global market expansion positions it well to capitalize on opportunities in the healthcare sector.

Masimo faces revenue challenges in Q2 but eyes rebound

Masimo's Q2 performance was impacted by revenue challenges in Healthcare and non-healthcare segments, leading to a revised revenue guidance for 2023.
The company is focusing on expense control measures, new product opportunities, and pricing discipline to drive profitability and rebound in business segments.
Despite challenges, Masimo remains optimistic about market opportunities in telehealth, consumer health, and the potential for revenue growth from products like Stork.
Ongoing litigation with Apple and uncertainties in customer order patterns pose challenges, but the company is implementing strategies to address these issues.

Masimo reports solid Q3 earnings, eyes growth in consumer health

Masimo's Q3 performance showcased strong revenue but challenges in sensor utilization recovery. The company's innovative products and expansion into consumer health signal growth potential. Addressing challenges in revenue guidance and market competition will be key focus areas for future success.

Masimo reports robust Q4 earnings, legal wins and growth opportunities

Masimo's strong Q4 performance and strategic focus on healthcare and hearables/wearables growth position the company well for 2024.
Legal victories in Apple litigation and FDA clearances for innovative products underscore Masimo's commitment to innovation and protecting its intellectual property.
While facing challenges in legal proceedings and product clearances, Masimo has opportunities to drive revenue growth through product innovation and market expansion.

Masimo reports strong Q1 earnings, plans consumer business separation

Masimo's Q1 2024 Earnings Call showcased robust financial performance, strategic revenue diversification, and plans for enhancing shareholder value through potential separation of the consumer business. While facing challenges in operational transitions and financial metrics scrutiny, the company is well-positioned for growth and value creation.

Masimo reports robust Q3 performance and outlines growth opportunities

Masimo's Q3 2024 earnings call showcased strong financial performance, strategic reviews, and growth initiatives. While facing challenges in margin progression and potential disruptions, the company is poised for growth with opportunities in revenue expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo SafetyNet® was used to evaluate the impact of remote patient monitoring and found reduced rates of hospital readmission and ED visits.

New Study Finds That Remote Patient Monitoring with Masimo SafetyNet® Significantly Reduced Rates of Hospital Readmission and ED Visits for Patients Recuperating at Home After Joint Replacement Surgery

A Media Snippet accompanying this announcement is available by clicking on this link. ORLANDO, Fla.

Building Your Dream Nursery: Why Masimo Stork Belongs on Your Baby Registry

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release second quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, August 6, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use.

Masimo to Report Second Quarter 2024 Financial Results After Market Close on Tuesday, August 6

NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Masimo Corporation (“Masimo”) (NASDAQ: MASI) for potential violations of the federal securities laws.

Lowey Dannenberg, P.C. is Investigating Masimo Corporation (NASDAQ: MASI) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm

GE HealthCare Technologies Inc

iRhythm Technologies

After taking a backseat in the first half, the healthcare sector is finally coming to life. The rising odds of a Trump presidency have improved prospects for the industry, validating the case for increasing positions in healthcare stocks to buy now.

3 Healthcare Stocks to Buy Now: Q3 Edition

Masimo's (MASI) R&D activities raise optimism about the stock.

Reasons to Add Masimo (MASI) Stock to Your Portfolio Now

NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Masimo Corporation (NASDAQ: MASI) resulting from allegations that Masimo may have issued materially misleading business information to the investing public.

MASI ANNOUNCEMENT: If You Have Suffered Losses in Masimo (NASDAQ: MASI), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Masimo (MASI) sues Politan to correct material misstatements in an ongoing proxy battle, rescheduling its annual meeting. Politan denies allegations and vows to prevent any further delay, criticizing Masimo's tactics.

Masimo (MASI) Sues Politan for Misstatements, Delays Annual Meet

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today responded to the Company's Board of Directors moving Masimo's Annual Meeting of Stockholders (the “Annual Meeting”), previously scheduled for July 25, 2024, to September 19, 2024. Politan also commented on the Board bringing a lawsuit in federal court against Politan and its founder and CIO Quentin Koffey. Mr.

Politan Comments on Masimo's Latest Entrenchment Maneuvers

Medical device maker Masimo Corp on Tuesday said it has started litigation against Politan Capital in a California federal court, seeking to force the activist investor to correct "material misstatements and omissions" in its proxy materials.

Masimo initiates legal action against activist investor Politan

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI), a global leader in noninvasive monitoring technologies and audio products, today announced that it has commenced litigation against Politan Capital Management LP (“Politan”) in federal court in California seeking to require Politan to correct material misstatements and omissions in Politan's proxy materials. The complaint alleges, among other things, that Quentin Koffey has assisted plaintiff's couns.

Masimo Files Complaint Seeking Injunction Requiring Politan to Correct Material Misstatements

NEW YORK , July 15, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Masimo Corporation (NASDAQ: MASI) resulting from allegations that Masimo may have issued materially misleading business information to the investing public. So What: If you purchased Masimo securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Rosen Law Firm Encourages Masimo Corporation Investors to Inquire About Securities Class Action Investigation - MASI

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended shareholders vote FOR the election of Politan's nominees, Darlene Solomon and Bill Jellison, to the Company's Board of Directors (the “Board”) at the Annual Meeting of Stockholders (the “Annu.

Leading Proxy Advisory Firm ISS Recommends Masimo Shareholders Vote FOR Both of Politan's Director Nominees

Proxy advisor Institutional Shareholder Services said boardroom change at medical technology company Masimo was "absolutely necessary." The unusually sharp report, a copy of which was viewed by CNBC, said shareholders should vote for activist Politan Capital Management's board nominees, Bill Jellison and Darlene Solomon.

Proxy advisor ISS says Masimo change is 'absolutely necessary' in brutal report

IRVINE, Calif.--(BUSINESS WIRE)--To ensure that Politan lies repeated over and over are not taken as fact, Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI) sets forth below facts in response to what we believe are some of Politan's and Quentin Koffey's most egregious and continuing misrepresentations. These misrepresentations include Politan's and Mr. Koffey's continuing efforts to sow mistrust and confusion regarding the proposed consumer joint venture. In response, Masimo CEO Joe.

Masimo Responds to Politan's Continuing Misrepresentations

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that leading proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) has recommended shareholders vote FOR the election of Politan's nominees, Darlene Solomon and Bill Jellison, to the Company's Board of Directors (the “Board”) at the Annual Meeting of Stockholders (the “Annual Meeting”), schedul.

Leading Proxy Advisory Firm Glass Lewis Recommends Masimo Shareholders Vote FOR Both of Politan's Director Nominees

Proxy advisory firm Glass Lewis said Masimo shareholders should vote for activist Politan nominees Darlene Solomon and Bill Jellison. The advisory firm said that Masimo CEO Joe Kiani ran "roughshod" over his "self-selected board," echoing concerns from the activist and some analysts.

Proxy advisor backs activist Politan nominees in scathing Masimo report

Masimo (MASI) gets an acquisition offer for its consumer business from an undisclosed entity. The deal is likely to close later in 2024.

Masimo (MASI) Gets Non-Binding Offer for Consumer Business

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today shared a statement from Michelle Brennan, an independent director of Masimo: “When I was approached last year by an executive search firm about the opportunity to potentially serve on Masimo's Board of Directors, I was immediately intrigued. Although I had no pre-existing relationship with Politan, I was very.

Masimo Independent Director Michelle Brennan Encourages Shareholders to Support an Urgently Needed Cultural Reset in the Company's Boardroom

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI) today highlighted the actions taken by Politan and Quentin Koffey since Masimo's 2023 Annual Meeting of Stockholders that directly contradict their purported commitment to good governance. Over the past twelve months, we believe Politan's Quentin Koffey has repeatedly acted against the best interests of Masimo and its stockholders. The summary provided below shows stockholders and the public the numer.

Masimo Exposes Politan's Governance Hypocrisy

Masimo's (MASI) second-quarter 2024 results are likely to reflect the strength in the Healthcare business.

Masimo (MASI) Preliminary Q2 Results Aided by Healthcare Unit

Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses

Masimo Corporation Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

IRVINE, Calif--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced preliminary revenue and select financial results for the second quarter ended June 29, 2024. Preliminary Second Quarter 2024 Revenue and Select Financial Results: Consolidated revenue is expected to be approximately $496 million, representing 9% growth on a reported basis and 10% growth on a constant currency basis; Healthcare revenue is expected to be approximately $344 million, representing 22% growth on a repor.

Masimo Announces Preliminary Second Quarter 2024 Revenue and Select Financial Results

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Masimo Corporation (NASDAQ: MASI) resulting from allegations that Masimo may have issued materially misleading business information to the investing public.

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Masimo Corporation Investors to Inquire About Securities Class Action Investigation – MASI

Masimo said on Monday a potential joint venture partner is prepared to offer $850 million to $950 million for its consumer business, which includes health and audio products.

News for Masimo Stock (MASI)